Medpace Holdings, Inc.
MEDPHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeMedpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. At a $18.72B market cap, Medpace Holdings, Inc. ranks as a large-cap company within healthcare. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
Market Cap
$18.72B
Beta
1.18
P/E (TTM)
36.31
P/E (Fwd)
33.70
EPS (TTM)
$18.43
EPS (Fwd)
$19.85
ROE
117.9%
ROA
18.7%
Cash
$705.3M
Total Debt
$146.0M
Free CF
$523.2M
52W Change
10.6%
Annual Financials
Cash vs Debt
Where MEDP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MEDP finished 17.47% above its 150-day moving average ($527.50) and 17.70% above its 200-day moving average ($526.46). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MEDP overbought or oversold?
At the October 20, 2026 close, MEDP's RSI(14) was 49.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Medpace Holdings, Inc. holds $705.3M in cash against $146.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $523.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 117.9% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 18.7% further supports the picture of efficient asset utilization. Revenue has grown from $1.46B (2022) to $2.53B (2025), reflecting a 73% increase over the period.
With cash comfortably exceeding debt, MEDP has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing MEDP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.